Flagship · Bulletin

Macro rationale

Live signals remain genuinely mid-range and unchanged from the 07-27 deep run: VIX 18.21 (-2.3% vs 200d SMA), HY OAS only +2bp above its SMA and still near the 18th historical percentile, 2s10s +0.36 (positive slope, below the 12m 0.54 average), extension inactive (QQQ +3.88%, wRSI 49.8). No cash escalator is live, so the NEUTRAL base band 5-15% binds with 15% as the hard ceiling and 14% as the enforced working reserve. Defensive weight comes from policy, not price: Warsh's hawkish hold at 3.50-3.75% with 9 of 18 dots leaning hike, core PCE 3.4%, forward ERP ~0.4%, NAAIM ~96 — near-max positioning into the July 29 FOMC — plus China's coastguard patrol expansion east of Taiwan. Against that, every named private-capital funder in the book is intact or strengthening: Alphabet's 2026 capex line lifted to $195-205B inside the ~$725B hyperscaler aggregate (MU/TSM/NVDA/AVGO/ANET), TSMC's announced 10% 2027 price hikes and $100B Arizona expansion, copper at all-time highs against a ~320k-tonne 2026 deficit (SCCO), term U3O8 $94-95.50/lb plus the 400GW nuclear target (CCJ), GEV's record $176B backlog with orders +88%, and FY2026 defense appropriated at $839.2B (P.L. 119-75). That is a late-cycle NEUTRAL with a defensive tilt — crowding and event risk rather than deterioration. This run's ad-hoc trigger is a single-name price shock (PSN -39.35% on 3.5× 20d ADV), which is idiosyncratic to a government-services prime whose book-to-bill and SHIELD task-order conversion were already failing, not a macro regime signal. Live book cash of 23.75% sits above the enforced ceiling and would be mechanically clipped; I bring intent cash to 13.93%, at the 14% working reserve, funded by the PSN close and the KTOS drift right-size rather than by force-selling intact compounders.

Thesis

Scope-locked event-driven patch: only PSN, KTOS, HEI may move; every other name is re-affirmed verbatim at its prior entry weight, delta 0. Two tickets. (1) PSN closes. The -39.35% single-day move on 3.5× 20d ADV is the market resolving a thesis I have journaled as broken for six consecutive runs: score 59, Q4 revenue -8% YoY, book-to-bill under 1.0, and the entry trigger — MDA SHIELD task-order conversion — never accelerated. The recent Qatar and Blatnik Bridge awards are civil infrastructure that dilutes rather than confirms the C5ISR/cyber thesis. This is a durability break plus a flow break, not a drawdown, so the LTCG-deferral tilt does not apply. (2) KTOS right-sized -3.03pp to 8.00%. Its 11.03% entry weight was never a conviction sizing — it arose from adds and drift off a deliberate 7.00% entry, and I journaled the intended trim last run. Score 62 near the floor, FCF still negative through the drone ramp, and the entry trigger (revenue scale + margin firming) remains unconfirmed. MACH-TB 2.0, Project Helios and the Pentagon drone-dominance program are intact — this is sizing discipline on drift, not a thesis exit, and the target now sits at live weight. HEI held unchanged at 10.23%: record Q2 net income +49%, ETG operating income +56%, inside the 12% cap; the 54x forward multiple is a watch item, not the confirmed growth-deceleration-plus-multiple invalidation. Mid-cap sleeve: LMT, DRS, VEEV and ORCL all screen, but scope lock plus stale_policy forbid opens — deferred

Reflection

Idiosyncratic government-services break (PSN -39% on 3.5x ADV), not a macro turn: hyperscaler capex, copper ATH, U3O8 $94+ and $839B FY2026 defense all unchanged.

The structural trap I have flagged for six runs finally resolved itself the expensive way: PSN was judged broken at score 50-59 since mid-July, but stale_policy plus the 18-position floor carried it until the market repriced it -39% in a day. Lesson I want to keep: when I judge a thesis broken and mechanics block the close, the cost is real and asymmetric — carrying a broken name on a position-count technicality is not neutral. MP (44) and LUNR (54) are still in that bucket. Also notable: PSN's last two 'positive' headlines were civil-infrastructure awards, i.e. the funder quietly changed pill

Positions (17)

• MUMicron Technologycompute

  hold3.86%88
  flow acceleratingconf

  Funder

  Durable US HBM3E/HBM4 memory franchise — 84.6% gross margin, FCF positive, the only US-domiciled leading-edge DRAM maker, run with genuine supply discipline after two decades of cycle abuse. Named flow: 16 multi-year Strategic Customer Agreements (~$100B contracted), the Anthropic multi-year supply deal, and ~$725B 2026 hyperscaler capex including Alphabet's raised $195-205B line; Morgan Stanley m

  Unwind

  DRAM/NAND spot collapse or HBM oversupply breaking the shortage thesis; hyperscaler capex cut; erosion of the 16-SCA contract book. CXMT capacity coming on at scale and compressing HBM pricing would be the specific competitive break.

  Catalyst

  Next quarterly print: HBM4 qualification progress and FY2027 revenue guide against the 84% growth consensus.

  Scenarios · 12mo targets

  $450.00 base

  $600.00 bull — HBM4 ramps sold-out through 2027 at contracted SCA pricing; memory stays structurally short and Micron holds share against SK Hynix.

  $300.00 bear — CXMT/Samsung capacity lands early, DRAM pricing rolls over and the cycle turns before the SCA book is fully realized.

• TSMTaiwan Semiconductor Manufacturingcompute

  hold5.83%86
  flow acceleratingconf

  Funder

  World-leading foundry with an effective monopoly at <=3nm — every meaningful AI accelerator routes through TSMC. >50% GM, prodigious FCF, famously disciplined capex, ~73% foundry share. Named flow: announced 10% 2027 price hikes (pure pricing power), the $100B Arizona expansion de-risking the Taiwan tail, CHIPS $6.6B Arizona disbursement, and CoWoS packaging scaling to 120-140k wpm for the hypersc

  Unwind

  Gross margin sustained <50% for two consecutive quarters; a rival closing the leading-edge yield gap; a Taiwan-strait event that Arizona capacity cannot offset.

  Catalyst

  Monthly revenue prints and the next quarterly capex guide; 2027 pricing confirmation with customers.

  Scenarios · 12mo targets

  $420.00 base

  $520.00 bull — 2027 price hikes stick, N2 ramps on yield, and Arizona removes the geopolitical discount from the multiple.

  $300.00 bear — Taiwan-strait escalation or a 2027 hyperscaler capex deceleration cuts leading-edge utilization and the pricing power narrative.

• NVDANVIDIAcompute

  hold3.61%74
  flow steadyconf

  Funder

  AI-accelerator franchise with the CUDA software moat — ~74.9% gross margin, fortress balance sheet, and developer lock-in no ASIC competitor has replicated. Named flow: ~$725B 2026 hyperscaler capex anchored on Blackwell/Rubin (MSFT ~$190B, AMZN ~$200B, GOOGL $195-205B, META $125-145B) plus the Stargate JV; ARK accumulating on the drawdown.

  Unwind

  Data-center revenue YoY <20% for two consecutive quarters; hyperscaler in-sourcing and AMD wins pushing competitor share toward the 25% TAM invalidation line; a compute export-control tightening that removes a named revenue geography.

  Catalyst

  Next data-center revenue print and Rubin ramp commentary; any further disclosure on the OpenAI/Ohio financing guarantees.

  Scenarios · 12mo targets

  $230.00 base

  $300.00 bull — Rubin ramps into unchanged 2027 capex, inference share holds above 70%, and the circular-financing worry proves cosmetic.

  $150.00 bear — AMD/ASIC share gains at MSFT, Meta, OpenAI and Anthropic bite while an OpenAI funding wobble makes the vendor-financing exposure real.

• ASMLASML Holdingcompute

  hold2.96%61
  flow steadyconf

  Funder

  EUV / High-NA monopoly — the single most irreplaceable tool in advanced semis, with no commercial-scale alternative at 2nm, a multi-year backlog and ~50% gross margin. Named flow: Norway GPFG holds, Coatue and Third Point added in Q1; the TSMC/Samsung/Intel 2025-27 EUV orderbook backstops cash flow, and the SK Hynix HBM4 capacity build pulls further litho tooling.

  Unwind

  Book-to-bill <0.7 for three consecutive quarters; a Dutch/US export-control tightening that removes a material share of the orderbook; a credible non-EUV patterning path at 2nm.

  Catalyst

  Next quarterly bookings print — the book-to-bill number is the whole tell.

  Scenarios · 12mo targets

  $1,400.00 base

  $1,750.00 bull — High-NA orders convert with 2nm ramps at three customers and bookings re-accelerate above 1.0 book-to-bill.

  $950.00 bear — China DUV substitution plus a capex-digestion year drops bookings and compresses a multiple that already ran 87% in H1.

• AVGOBroadcomcompute

  hold2.92%63
  flow steadyconf

  Funder

  Custom-silicon ASIC leader (~70% share) plus the VMware infrastructure-software moat — huge FCF, $7B+ annual buyback, serial dividend grower, and one of the best capital-allocation records in semis. Named flow: Google TPU multi-generation, Meta MTIA and the Anthropic 3.5GW ASIC programs, with Alphabet's capex raised to $195-205B feeding the pipeline directly.

  Unwind

  AI custom-chip revenue stalling below a $25B annual run-rate; full hyperscaler in-sourcing displacing the ASIC design franchise; VMware renewal churn breaking the software annuity.

  Catalyst

  Next quarterly AI-segment revenue and bookings disclosure.

  Scenarios · 12mo targets

  $480.00 base

  $600.00 bull — AI segment compounds past a $100B 2027 run-rate on TPU/MTIA/Anthropic ramps while VMware renewals hold price.

  $330.00 bear — A hyperscaler brings a program in-house or delays a generation, and VMware churn shows up in the software line.

• ANETArista Networkscompute

  hold2.60%67
  flow acceleratingconf

  Funder

  Durable hyperscaler-networking franchise and consistent share-gainer since 2004 — ~61.9% gross margin, net cash, no debt, and the single-image EOS software moat that keeps switching costs high. Jayshree Ullal's capital discipline is a two-decade record. Named flow: Microsoft and Meta as named largest customers funding ~30% growth, guidance raised twice, record revenues, Morgan Stanley PT $190 as e

  Unwind

  Microsoft+Meta combined concentration >50% with revenue decelerating; Spectrum-X or whitebox displacing EOS in a named hyperscaler footprint; gross margin breaking below the mid-50s.

  Catalyst

  Next quarterly print — AI-cluster ethernet revenue and 2027 guide.

  Scenarios · 12mo targets

  $200.00 base

  $250.00 bull — Ethernet wins the AI-fabric standard war outright and Arista holds 60%+ margins while adding a third hyperscaler at scale.

  $130.00 bear — NVIDIA Spectrum-X takes a named hyperscaler footprint and customer concentration turns into a pricing problem.

• CCJCamecoenergy

  hold7.05%67
  flow steadyconf

  Funder

  Tail-risk hedge slot (§5.3): tier-1 Saskatchewan uranium franchise (McArthur River/Cigar Lake) plus the 49% Westinghouse JV with Brookfield — irreplaceable, permitted, low-cost tonnes in a stable jurisdiction. Named flow: term U3O8 at $94-95.50/lb vs a legacy contract book near $60 repricing upward, Kazatomprom's 8Mlb output cut sustaining the deficit, the DOE $17.5B AP1000 loan commitment and the

  Unwind

  Uranium spot/term price collapse; contract-book erosion or failure to reprice legacy contracts upward; a reactor-build program cancellation. Score drift alone is not a trigger.

  Catalyst

  Next contracting-volume disclosure and the monthly UxC/TradeTech term-price print.

  Scenarios · 12mo targets

  $95.00 base

  $130.00 bull — Term uranium holds above $95, legacy contracts reprice, and Westinghouse AP1000 orders convert into JV earnings.

  $60.00 bear — Term price rolls over, a reactor program slips, and Cameco's contracting cadence stalls with no repricing catch-up.

• GEVGE Vernovaenergy

  hold4.92%61
  flow acceleratingconf

  Funder

  Gas-turbine and grid franchise with genuine pricing power — record ~$176B backlog, turbines sold out through 2030, 10-20% price realization on new orders, quadrupled FCF, and a three-player global oligopoly. Named flow: Norway GPFG added post-spin; total orders +88% with revenue +22%; hyperscaler and xAI gas-power procurement plus the Chevron behind-the-meter JV pull the backlog forward.

  Unwind

  Gas-turbine backlog cancellation or a hyperscaler power-capex cut; wind losses widening enough to consume gas-segment profit; EV/EBITDA breaching the ~25x exit threshold with growth decelerating.

  Catalyst

  Next quarterly order book — gas orders vs the wind segment's -40% order decline.

  Scenarios · 12mo targets

  $750.00 base

  $950.00 bull — Gas orders keep compounding at +88% with 10-20% price realization and wind is ring-fenced or exited outright.

  $480.00 bear — Wind losses widen enough to eat gas profit while a 2027 datacenter power-capex pause slows order intake.

• SCCOSouthern Copperenergy

  hold8.01%68
  flow steadyconf

  Funder

  Tail-risk hedge slot (§5.3): lowest-cost major copper producer with the industry's largest reserve base, 59.8% gross margin, FCF positive and a large dividend — Grupo Mexico ownership enforces capital discipline. Named flow: copper at all-time highs against a ~320k-tonne 2026 deficit, ~14 days of exchange inventory, AI/datacenter demand ~30% of new copper by 2030 (BloombergNEF), and BHP reporting

  Unwind

  Copper price collapse breaking the deficit thesis; Tia Maria / Los Chancas permitting reversal; a dividend cut signalling balance-sheet stress.

  Catalyst

  Tia Maria / Los Chancas permitting progress; quarterly copper realized-price and cost print.

  Scenarios · 12mo targets

  $165.00 base

  $200.00 bull — The 2026 deficit persists, Tia Maria permits clear, and grid/AI copper demand keeps prices at records with SCCO's cost lead intact.

  $110.00 bear — A China demand air-pocket cracks copper, Peruvian permitting reverses, and the dividend gets rebased.

• MPMP Materialsenergy

  hold0.25%44
  flow softeningconf

  Funder

  Only scaled US rare-earth mine plus magnet producer — Mountain Pass is a genuinely irreplaceable asset against China's ~98% magnet control. Named flow is a government-backstopped moat: DoD $400M Series A preferred, a $150M loan, a 10-year $110/kg NdPr price floor and a 10-year magnet offtake for the 10X facility, plus the Apple long-term magnet agreement.

  Unwind

  FCF stays negative through the magnet ramp; the China MOFCOM blacklist chokes processing-technology access materially; 10X construction slips; the DoD price floor or offtake is repealed or renegotiated.

  Catalyst

  10X Texas magnet facility construction milestones and the next NdPr production/FCF print.

  Scenarios · 12mo targets

  $55.00 base

  $85.00 bull — 10X commissions on schedule, magnet revenue scales under the DoD offtake, and FCF inflects positive with the $110/kg floor underwriting it.

  $30.00 bear — The China blacklist blocks processing tech, 10X slips again, and FCF stays negative deep into 2027.

• NEMNewmont Corporationenergy

  hold7.52%85
  flow steadyconf

  Funder

  Tail-risk equity hedge (§5.3): largest gold producer with tier-1 long-life assets, strong post-Newcrest FCF and dividend, and visibly improving cost discipline after the divestiture program. Named flow: sustained central-bank gold accumulation as reserve diversification, a hawkish Fed hold with core PCE at 3.4% keeping the stagflation hedge live, and TD Cowen's upgrade to buy at a $127 target.

  Unwind

  Cost overruns or mine disappointments breaking FCF and the dividend; durable disinflation plus a real-rate surge removing the stagflation-hedge rationale; a peer-relative multiple stretch with production guidance cuts.

  Catalyst

  Next quarterly AISC and FCF print; FOMC language on the hold-vs-hike path.

  Scenarios · 12mo targets

  $120.00 base

  $155.00 bull — Central banks keep buying, real rates fall from restrictive levels, and post-Newcrest AISC discipline converts gold strength into FCF and buybacks.

  $80.00 bear — Durable disinflation plus a real-rate surge de-rates gold while cost inflation at tier-1 mines squeezes the dividend.

• KTOSKratos Defensedefense

  hold11.03%62
  flow steadyconf

  Funder

  Tactical drones (XQ-58A Valkyrie), hypersonics and turbine engines — a scarce non-prime supplier of attritable airframes with 24.2% gross margin. Named flow intact: DoD MACH-TB 2.0 IDIQ prime ($1.45B ceiling, 5-year), Project Helios $68.3M hypersonic-materials single award, USMC Valkyrie MUX mods, $2B+ funded backlog, the Pentagon drone-dominance program (22k+ units) and ARK accumulation. FY2026 d

  Unwind

  Backlog or contract cancellations; margin failing to inflect through the drone ramp; a DoD unmanned-systems funding cut, or FY2027 appropriations slipping past October 1 with new-start prohibitions biting the Valkyrie ramp.

  Catalyst

  Next quarterly print — revenue scale and the first margin inflection through the drone ramp; FY2027 appropriations markup.

  Scenarios · 12mo targets

  $70.00 base

  $95.00 bull — Drone-dominance procurement converts the $2B funded backlog into scale revenue and margin inflects positive with FCF turning.

  $40.00 bear — FCF stays negative, the margin inflection slips another year, and an FY2027 CR freezes new-start unmanned programs.

• HEIHEICOdefense

  hold10.23%68
  flow steadyconf

  Funder

  Defense/aero aftermarket compounder and a textbook 20-30 year franchise — the Mendelson family has owned and run it since 1957, compounding FCF at 20%+ with a disciplined serial-acquisition model ($1B+/yr) and PMA parts approvals that are effectively unrepeatable. Named flow: record Q2 net income +49% YoY, Electronics Group operating income +56%, FSG $929M vs $864M consensus, funded by NDAA mandat

  Unwind

  Organic growth decelerating below 6% with margin compression; forward P/E sustained above 50x WITH growth deceleration confirmed (valuation alone is not the trigger); a value-destroying large acquisition or a Mendelson management exodus.

  Catalyst

  Next quarterly print — organic FSG growth rate and acquisition cadence.

  Scenarios · 12mo targets

  $400.00 base

  $480.00 bull — Aftermarket MRO demand plus tuck-in acquisitions keep double-digit organic growth and 20%+ FCF compounding intact.

  $290.00 bear — Organic growth slips below 6% with margin compression while a 54x forward multiple de-rates toward the 50x invalidation line.

• LLYEli Lillybiology

  hold6.09%73
  flow steadyconf

  Funder

  Premier pharma compounder — the Mounjaro/Zepbound GLP-1 franchise (~60% US share) plus oral orforglipron (Foundayo, FDA-approved) and retatrutide in Phase 3 (~70lb loss), on 82.9% gross margin with strong FCF. Named flow: the $27B US manufacturing build-out (also the domestic-production answer to the July 31 Section 232 pharma tariff), Norway GPFG and large AM holders, and a 12-deal 2026 acquisiti

  Unwind

  Tirzepatide US script share falling >5pts to Novo over two quarters; retatrutide Phase 3 disappointing; IRA/MFP negotiation reaching the GLP-1 franchise in an IPAY cycle.

  Catalyst

  Retatrutide Phase 3 readout; next quarterly incretin revenue and script-share print; IPAY 2028 selection list.

  Scenarios · 12mo targets

  $1,200.00 base

  $1,450.00 bull — Orforglipron scales the oral market, retatrutide reads out clean, and $27B of capacity converts demand backlog into revenue.

  $850.00 bear — Novo's oral takes measurable US share, retatrutide disappoints, and IRA negotiation reaches the incretin franchise.

• VRTXVertex Pharmaceuticalsbiology

  hold4.07%81
  flow steadyconf

  Funder

  Durable biology compounder: the cystic-fibrosis monopoly (Trikafta/Alyftrek) is a self-funding cash engine with 86.8% gross margin, no meaningful competition, and a fortress net-cash balance sheet. Named flow: the $10B Crinetics acquisition adding up to ~$5B of endocrine revenue potential, Casgevy commercializing across 12+ jurisdictions under the Medicare Cell & Gene access model, and Journavx no

  Unwind

  The CF franchise eroding faster than non-CF revenue can replace it; the Crinetics integration destroying value or pushing forward P/E toward the 30x invalidation threshold; a pipeline failure in pain or gene therapy.

  Catalyst

  Crinetics deal close and financing detail; next quarterly CF revenue plus Journavx launch metrics.

  Scenarios · 12mo targets

  $520.00 base

  $620.00 bull — Crinetics diversifies revenue away from CF concentration while Journavx scales and Alyftrek extends the CF annuity.

  $380.00 bear — CF erodes faster than non-CF replaces it and the $10B Crinetics deal proves dilutive to FCF and the multiple.

• ARGXargenxbiology

  hold3.79%69
  flow acceleratingconf

  Funder

  argenx — the Vyvgart/Vyvgart Hytrulo (efgartigimod) FcRn autoimmune franchise: a first-mover platform with a decade of indication runway, self-funded, commercial-stage, high-margin and net cash. Named flow: the FDA label expansion to all gMG serotypes (~18% TAM expansion), Sanofi's riliprubart Phase 3 failure in CIDP removing the nearest competitive threat, and advancing myositis/Sjogren's data fr

  Unwind

  Vyvgart revenue growth stalling; a pipeline indication failure in myositis or Sjogren's; a competitor FcRn entrant taking measurable share.

  Catalyst

  Myositis and Sjogren's data readouts; next quarterly Vyvgart/Hytrulo revenue print.

  Scenarios · 12mo targets

  $850.00 base

  $1,050.00 bull — Hytrulo prefilled-syringe conversion plus myositis/Sjogren's label expansion compounds Vyvgart toward the $16B 2036 projection.

  $600.00 bear — gMG growth decelerates, a pipeline indication misses, and a rival FcRn takes measurable share in CIDP.

• LUNRcompute

  hold1.26%54
  flow steadyconf

  Funder

  Intuitive Machines — named government backlog is the whole thesis: NASA Near Space Network IDIQ ($4.82B ceiling, active), a $148.3M firm-fixed-price CLPS task order, the Space Force Andromeda IDIQ ($6.2B ceiling) and ~$1.1B of contracted backlog. Small speculative sleeve position sized accordingly; capital is flowing to US-listed space infrastructure as SpaceX stays private.

  Unwind

  Backlog conversion stalling; the profitability pathway breaking; a NASA CLPS or SDA program funding cut; further insider selling. Resolve at the first non-stale, non-scope-locked deep run.

  Catalyst

  Next CLPS mission milestone and the quarterly backlog-conversion/cash-burn print.

  Scenarios · 12mo targets

  $12.00 base

  $20.00 bull — CLPS and Near Space Network task orders convert on schedule, cash burn narrows, and the 28.85% short interest unwinds.

  $5.00 bear — A mission failure or NASA program funding cut stalls backlog conversion and forces dilutive financing.

Warnings

• cluster_cap_trimmed: ai_load 35.01% > 35% — pro-rata trim across [MU, TSM, NVDA, ASML, AVGO, ANET, CCJ, GEV, LUNR] (§2/§3)
• §2 cap re-applied after pillar tilt: MU
• §2 cap re-applied after pillar tilt: TSM
• §2 cap re-applied after pillar tilt: NVDA
• §2 cap re-applied after pillar tilt: ASML
• §2 cap re-applied after pillar tilt: AVGO
• §2 cap re-applied after pillar tilt: ANET
• §2 cap re-applied after pillar tilt: CCJ
• §2 cap re-applied after pillar tilt: GEV
• §2 cap re-applied after pillar tilt: LUNR
• hedge_floor: only 2/3 tail-risk names held (floor escalated: AI-load 35% > 30%) — open a gold/oil/diversified-commodity hedge (§5.3); uranium & power-gen do not count
• live_sizing: 1 ticket(s) re-expressed against the executed ledger (§6.6)
• reserve_gate: intent cash 10.9% below the §5.4 working reserve 14% — new deployment gated: shrunk MP (buying cannot drain the reserve; trims/closes rebuild it)
• ledger reconcile: re-emitting unexecuted buys for MP

Conviction-lock actions

1. Turn 1ConvictionGuard (§6.5d)

   —

Cost breakdown

Per-call cost computed from cost.js pricing constants (Opus 4.7, Sonnet 4.6, Haiku 4.5). Cache-read tokens billed at 10% of input. See Cost & ROI for the rolling 30-day ledger.